
The benefit of cholesterol-lowering drug therapy in patients with existing coronary heart disease zzso is well established through clinical zzso Prevention of zzso coronary morbidity and mortality in zzso patients is called secondary zzso In contrast, primary prevention is delaying or preventing altogether zzso There are three categories of primary zzso zzso zzso and long-term zzso A recent clinical trial has documented benefit of cholesterol-lowering drugs for prevention of coronary morbidity and mortality and total mortality in zzso middle-aged zzso This trial lends support for including aggressive cholesterol reduction in high-risk primary zzso However, for such therapy to be cost effective at zzso prices of cholesterol-lowering drugs, only those patients in the higher ranges of risk can be selected for zzso This leaves a large number of people at moderately high risk for premature zzso because of high cholesterol zzso These persons deserve increased professional attention to risk zzso In general the zzso approach is zzso The latter approach includes eliminating other risk factors, zzso cigarette smoking and hypertension, and reducing serum cholesterol levels by decreased zzso of saturated fatty zzso cholesterol, and excess total zzso Some zzso patients may require low doses of cholesterol-lowering drugs to achieve the goals for cholesterol zzso Finally, public health strategies need to be developed for applying the same zzso approach for the general population for reducing the overall zzso of zzso 

